Imugene Limited

ASX (AUD): Imugene Limited (IMU)

Last Price

0.038

Today's Change

-0.001 (2.56%)

Day's Change

0.038 - 0.039

Trading Volume

11,101,427

Profile
IMU

Exchange:  Australian Securities Exchange Australian Securities Exchange

Currency:  AUD AUD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Ms. Leslie Chong Ms. Leslie Chong

Full Time Employees:  0 0

IPO Date:  1998-12-31 1998-12-31

CIK: 

ISIN:  AU000000IMU9 AU000000IMU9

CUSIP:  Q48850103 Q48850103

Beta:  3.34 3.34

Last Dividend:  0.00 0.00

Dcf Diff:  0.03 0.03

Dcf:  0.01 0.01

Description

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Address

4-6 Bligh Street,
Sydney, NSW 2000, AU

61398245254

http://www.imugene.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment